Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Among authors: asada k. Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175. Oncotarget. 2016. PMID: 27659536 Free PMC article.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kukita A, et al. Among authors: asada k. Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4. Biochem Biophys Res Commun. 2019. PMID: 30955858
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H. Uehara Y, et al. Among authors: asada k. PLoS One. 2015 Jun 4;10(6):e0128066. doi: 10.1371/journal.pone.0128066. eCollection 2015. PLoS One. 2015. PMID: 26043110 Free PMC article.
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kojima M, et al. Among authors: asada k. BMC Cancer. 2019 May 15;19(1):455. doi: 10.1186/s12885-019-5638-9. BMC Cancer. 2019. PMID: 31092221 Free PMC article.
Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report.
Sone K, Eguchi S, Asada K, Inoue F, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Matsumoto Y, Hiraike-Wada O, Oda K, Osuga Y, Fujii T. Sone K, et al. Among authors: asada k. Mol Clin Oncol. 2020 Aug;13(2):141-145. doi: 10.3892/mco.2020.2053. Epub 2020 May 27. Mol Clin Oncol. 2020. PMID: 32714537 Free PMC article.
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Matsushita H, et al. Among authors: asada k. J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375. J Immunother Cancer. 2020. PMID: 32461346 Free PMC article.
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. Matsushita H, et al. Among authors: asada k. Oncoimmunology. 2017 Jun 16;6(8):e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017. Oncoimmunology. 2017. PMID: 28920005 Free PMC article.
558 results